NCT00346255 (Clinical Trial / Lorvotuzumab Mertansine / BB-10901 / IMGN-901)

Study Title
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma (IMGN901) (NCT00346255)

Trial Description
Monoclonal antibodies, such as BB-10901 (also known as lorvotuzumab mertansine, huN901-DM1,  huN901-SPP-DM1, IMGN-901 and IMGN901 TAP) , can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.

This phase I trial is studying the side effects and best dose of BB-10901 in treating patients with relapsed and/or refractory multiple myeloma.

This trial is sponsored by ImmunoGen, Inc. [1]

Study Data

  • Condition: Multiple Myeloma
  • Interventions:
    • Drugs used in this trial
      • BB-10901 (Lorvotuzumab Mertansine / IMGN-901)
  • Phase: I
  • Enrollment: 37
  • Start: April 2005
  • Completion: March 2011
  • Last verified: April 2013

Study Schematic 

(Coming soon)

Click here to Return to Drug map

Last Editorial review: August 10, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.